CBD business in Switzerland — legal framework

TL;DR

• CBD flower <1 % THC: legal as tobacco substitute (TobPA since 1.10.2024).
• Oral CBD oils: Novel Food status — Switzerland accepts with correct labeling.
• CBD cosmetics: legal under CosmO with INCI declaration.
• Health claims (anxiety, pain, sleep): forbidden without TPA authorization.

Regulatory pitfalls

• THC limit: 1.0 % total (incl. THCA after decarboxylation).
• Ban on therapeutic advertising — even indirect claims are problematic.
• CBD food: only with FSVO Novel Food authorization.
• Import: CBD from EU possible, customs declaration required.

The three legal traps in Swiss CBD business: Novel Food, tobacco tax, health claims

First, Novel Food: CBD extracts intended for ingestion are in principle treated in Switzerland, as in the EU, as novel foods requiring authorisation. Selling oils as a “supplement” without authorisation sits in a grey zone; the usual workaround – declaring them as aroma products or cosmetics – demands rigorous labelling and no dosage recommendation.

Second, tobacco tax: CBD flower and hash intended for smoking are subject to tobacco tax calculated on the retail price. This levy belongs in the pricing model from day one, otherwise the margin collapses. Registration, declaration and correct price marking run through the FOCBS.

Third, health claims: statements such as “relieves pain”, “eases anxiety” or “anti-inflammatory” turn a consumer product into a therapeutic product under the Therapeutic Products Act. This is the most frequent objection in cantonal inspections and is entirely avoidable by limiting communication to strain, lab data, terpene profile and origin.

• Oral CBD extracts: clarify Novel Food status before market entry, not after.
• Smokable CBD: include tobacco tax on the retail price in your pricing model.
• No health claims – not in blogs, newsletters or customer reviews either.
• Document and retain accredited-lab batch analytics (THC < 1 %) for every batch.

Swiss enforcement practice and cantonal controls

In Switzerland, the enforcement of food, therapeutic products, and tobacco legislation is primarily the responsibility of the cantonal authorities, in particular the cantonal chemists and the cantonal therapeutic products control authorities. Since the cantons have a certain degree of discretion in enforcement, practice shows varying handling of inspections and complaints. While some cantons are very proactive in inspecting points of sale and meticulously analysing product declarations, other authorities act more reactively in response to reports. For CBD companies, this means they cannot blindly rely on the practice in a neighbouring canton, but must carefully analyse local conditions.

An official complaint can have serious financial consequences, ranging from sales bans to the confiscation of the entire inventory. Common triggers for such measures are unauthorised health claims on websites or packaging, as well as the incorrect classification of products. The cantonal laboratories work closely with the Federal Food Safety and Veterinary Office (BLV) and Swissmedic to ensure compliance with federal legislation. A transparent and professional dialogue with the competent cantonal enforcement authorities even before the start of sales can help to clear up misunderstandings at an early stage and avoid costly recalls.

• Responsibility lies with the cantonal laboratories and therapeutic products authorities.
• Varying intensity of inspections and interpretation of discretionary scope depending on the canton.
• Risk of sales bans, confiscations, and costly proceedings in the event of infringements.
• Cooperation with the authorities minimises the risk of unforeseen sanctions.

Quality assurance and laboratory analysis

Compliance with the legal THC limit of less than one percent is the most critical legal survival issue for Swiss CBD producers and distributors. If this limit is exceeded even slightly, the product falls under the Narcotics Act, which entails criminal consequences for those responsible. To prevent this, seamless quality assurance is essential, starting from raw material production right through to the end product. Every batch must be analysed by an accredited Swiss laboratory, with the focus on the total THC content, which is calculated from active THC and the precursor THCA.

In addition to the THC content, laboratory analyses must also prove the purity of the products, particularly with regard to pesticides, heavy metals, and microbiological contaminants. Since CBD flowers serve as tobacco substitutes or raw materials for cosmetics, strict limit values apply to harmful substances. Swiss distributors are legally required to have the corresponding certificates of analysis ready for each batch and to present them to the authorities upon request. Seamless traceability from the end consumer back to the agricultural farm is not only a legal obligation, but also a decisive argument for the credibility and professionalism of one's own company.

• Compliance with the total THC limit of less than one percent to avoid criminal prosecution.
• Mandatory batch analysis by an accredited laboratory for every product batch.
• Testing for contaminants such as pesticides, heavy metals, and moulds.
• Ensuring seamless traceability across the entire supply chain.

Distribution channels and advertising restrictions

The distribution and advertising of CBD products in Switzerland are subject to strict legal limits, which vary significantly depending on the product category. Since the entry into force of the new Tobacco Products Act in October 2024, the same strict advertising and youth protection regulations apply to smokeable CBD products as to conventional tobacco products. This includes, among other things, a clear ban on sales to minors as well as extensive restrictions on billboard and cinema advertising. Online shops must use technical measures such as age verification systems to ensure that minors under eighteen years of age cannot access these products.

In digital marketing, CBD companies also face significant hurdles set up by the major technology platforms. Many social networks and search engines generally prohibit paid advertising for cannabis products, regardless of the THC content or legal classification in the respective country. Marketing must therefore focus primarily on organic relationship building, search engine optimization, and informative content. In doing so, meticulous care must be taken to ensure that no indirect health claims or misleading representations are used, as this immediately attracts the attention of the supervisory authorities.

• Strict youth protection and advertising regulations for smokeable CBD products since October 2024.
• Need for reliable age verification systems in e-commerce.
• Restrictions and advertising bans on major digital advertising platforms.
• Focus on organic marketing channels in strict compliance with therapeutic products law.

Liability, insurance, and risk management

As distributors of CBD products, Swiss companies bear full product liability for the safety and compliance of their goods. Should a consumer suffer harm due to a defective or contaminated product, the distributor faces significant civil liability claims for damages. Professional risk management is therefore indispensable in order to identify and minimize potential hazards at an early stage. This also includes providing clear emergency plans in the event of a product recall, including rapid contact with Tox Info Suisse in the event of suspected poisoning or intolerance.

Covering these risks through classic public and product liability insurance often proves to be a challenge in the cannabis sector. Many traditional Swiss insurance companies exclude risks associated with cannabis products from their standard policies or demand high risk surcharges. CBD entrepreneurs must therefore seek specialized insurance solutions and examine the exact scope of coverage in detail. Only those who understand their liability risks and secure them properly through contracts and insurance can protect their business from existential financial damage in the long term.

• Full product liability of the person placing the product on the market for the safety of all sold goods.
• Establishment of emergency plans and cooperation with bodies such as Tox Info Suisse.
• Difficulties in finding suitable business and product liability insurance.
• Need for tailored insurance solutions to cover specific industry risks.

FAQ